Daratumumab Breaks Platelet Transfusion Refractoriness in Aplastic Anemia
A small trial finds daratumumab resolved transfusion refractoriness in 8 of 10 aplastic anemia patients, with some achieving full hematopoietic recovery.
Summary
Researchers at a leading Chinese hematology institute tested daratumumab — a CD38-targeting antibody — in 10 aplastic anemia patients who had stopped responding to platelet transfusions. Eight of the ten patients saw their transfusion refractoriness resolve. More strikingly, four patients achieved hematopoietic recovery, meaning their bone marrow began producing blood cells again. Three of those four improved across multiple blood cell lineages on daratumumab alone, without additional therapies. This suggests CD38-expressing immune cells may be driving both platelet destruction and broader bone marrow suppression in aplastic anemia. The findings open a potential new treatment avenue for a condition that carries high mortality risk when transfusions fail.
Detailed Summary
Platelet transfusion refractoriness is a life-threatening complication in aplastic anemia, leaving patients vulnerable to uncontrolled bleeding when donated platelets are rapidly destroyed before they can function. Standard approaches to managing this complication are limited, making new therapeutic strategies urgently needed.
Researchers from the Institute of Hematology and Blood Diseases Hospital in Tianjin, China, conducted a registered clinical trial (NCT05832216) exploring whether daratumumab — a monoclonal antibody that targets CD38, a protein highly expressed on certain immune and plasma cells — could overcome platelet transfusion refractoriness in aplastic anemia patients.
In this small cohort of 10 patients, 8 (80%) experienced resolution of platelet transfusion refractoriness after daratumumab administration. Beyond correcting platelet responses, 4 patients achieved meaningful hematopoietic recovery. Remarkably, 3 of these 4 showed improvements across multiple blood cell lineages — red cells, white cells, and platelets — even when treated with daratumumab as a monotherapy, suggesting the drug may address an underlying immune-mediated mechanism suppressing overall marrow function.
These results imply that CD38-positive cells, possibly including autoreactive plasma cells or NK cells, play a role not only in platelet destruction but potentially in the broader immune pathology of aplastic anemia. Daratumumab's ability to deplete these cells may partially rehabilitate bone marrow function beyond just correcting transfusion refractoriness.
Caveats are significant: the study is very small (n=10), lacks a control arm, and the abstract does not detail follow-up duration, dosing regimen, or adverse event profiles. Larger randomized trials are needed before daratumumab can be considered a standard intervention, but these early signals are clinically meaningful for a population with few options.
Key Findings
- 8 of 10 aplastic anemia patients resolved platelet transfusion refractoriness after daratumumab treatment.
- 4 patients achieved hematopoietic recovery, suggesting broader bone marrow benefit.
- 3 patients showed multilineage blood cell count improvements on daratumumab monotherapy alone.
- CD38 targeting may address immune-mediated platelet destruction and marrow suppression simultaneously.
- Results support CD38-expressing immune cells as drivers of aplastic anemia pathology.
Methodology
This was a registered prospective clinical trial (NCT05832216) enrolling 10 aplastic anemia patients with platelet transfusion refractoriness who received daratumumab. The study was conducted at a national hematology research center in China. Only the abstract is available, limiting detailed assessment of dosing, follow-up duration, and safety data.
Study Limitations
The cohort is very small (n=10) with no control group, making efficacy estimates preliminary and potentially subject to selection bias. Adverse event profiles, optimal dosing, and long-term outcomes are not described in the available abstract. Generalizability is uncertain until larger, multicenter randomized trials are completed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.